The ClinGen PTEN Expert Panel considers evidence for <50% PTEN lipid phosphatase activity as evidence for pathogenicity (PS3) [36], and cancer resulting from reduced lipid phosphatase activity of PTEN is most often linked to reduced suppression of PI3K/AKT pathway activity [46, 80, 81]. Here, PTEN is linked to cancer.